Alzheimer’s Disease Clinical Trials

DelveInsight’s analysis highlights that the Alzheimer’s Disease pipeline comprises over 110 key companies actively engaged in developing more than 120 treatment therapies.

Alzheimer’s Disease Overview:

Alzheimer’s disease (AD) is a neurodegenerative disorder that causes the progressive deterioration of brain cells and is the leading cause of dementia, characterized by cognitive decline and the loss of independence in daily life. AD is considered a multifactorial condition, with two primary hypotheses proposed for its development: the cholinergic hypothesis and the amyloid hypothesis. Several risk factors also contribute to its onset, including aging, genetic predisposition, head trauma, vascular conditions, infections, and environmental influences.

The symptoms of Alzheimer’s disease vary with disease stage. Based on the severity of cognitive decline, AD is categorized into preclinical (presymptomatic), mild, and dementia-stage, which differ from the DSM-5 classification of the condition.

The earliest and most common symptom is episodic short-term memory loss, while long-term memory is often preserved in the early stages. As the disease progresses, patients may experience difficulties with problem-solving, judgment, executive functioning, and motivation, leading to issues with multitasking and abstract thinking. Executive dysfunction in the early phase may range from mild to severe.

Request for a detailed insights report on Alzheimer’s Disease pipeline insights

“Alzheimer’s Disease Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Alzheimer’s Disease Therapeutics Market.

Key Takeaways from the Alzheimer’s Disease Pipeline Report

• DelveInsight’s Alzheimer’s Disease pipeline report highlights a dynamic landscape, featuring over 110 active companies developing more than 120 therapeutic candidates for Alzheimer’s treatment. Leading industry players, including AriBio, Eli Lilly, Cognition Therapeutics, AbbVie, Allyx Therapeutics, Cassava Sciences, BioVie, Novo Nordisk, Alector, Longeveron, TrueBinding, VT BIO, Luye Pharma, Lexeo Therapeutics, Merck, Regeneration Biomedical, Alnylam, Sinotau Pharmaceutical, Eisai, Shanghai Hengrui, and others, are advancing novel therapies to enhance the treatment paradigm.

• Notable pipeline candidates in various stages of development include AR1001, NE3107, LY3372689, CT1812, ABBV-916, ALX-001, and more.

• In July 2024, the U.S. FDA approved Kisunla™ (donanemab-azbt) for adults with early symptomatic Alzheimer’s disease. Clinical studies demonstrated a 35% reduction in cognitive and functional decline over 18 months compared to placebo and a 39% lower risk of progression to the next disease stage. Kisunla is notable for its limited-duration treatment regimen, with nearly half of the study participants completing the course within 12 months.

Alzheimer’s Disease Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Alzheimer’s Disease Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer’s Disease treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Alzheimer’s Disease market.

Download our free sample page report on Alzheimer’s Disease pipeline insights

Alzheimer’s Disease Emerging Drugs

• AR1001: AriBio Co., Ltd.

• NE3107: BioVie

• LY3372689: Eli Lilly & Co.

• CT1812: Cognition Therapeutics

• ABBV-916: AbbVie Inc.

• ALX-001: Allyx Therapeutics, Inc.

Alzheimer’s Disease Companies

Over 110 leading companies are currently working on developing therapies for Alzheimer’s disease, with AriBio Co., Ltd. and BioVie having candidates in the most advanced stage, currently in Phase III clinical trials.

DelveInsight’s report covers around 120+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Alzheimer’s Disease Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Alzheimer’s Disease Therapies and Key Companies: Alzheimer’s Disease Clinical Trials and advancements

Alzheimer’s Disease Pipeline Therapeutic Assessment

• Alzheimer’s Disease Assessment by Product Type

• Alzheimer’s Disease By Stage

• Alzheimer’s Disease Assessment by Route of Administration

• Alzheimer’s Disease Assessment by Molecule Type

Download Alzheimer’s Disease Sample report to know in detail about the Alzheimer’s Disease treatment market @ Alzheimer’s Disease Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Alzheimer’s Disease Current Treatment Patterns

4. Alzheimer’s Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Alzheimer’s Disease Late-Stage Products (Phase-III)

7. Alzheimer’s Disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Alzheimer’s Disease Discontinued Products

13. Alzheimer’s Disease Product Profiles

14. Alzheimer’s Disease Key Companies

15. Alzheimer’s Disease Key Products

16. Dormant and Discontinued Products

17. Alzheimer’s Disease Unmet Needs

18. Alzheimer’s Disease Future Perspectives

19. Alzheimer’s Disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Alzheimer’s Disease Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/